Our studies also demonstrate that neurons may not require relatively high levels of frataxin protein for their normal functionality, which is a promising result in terms of designing therapeutic strategies needed to increase frataxin levels in FRDA patients. This evidence concerns the gene FXN and Friedreich ataxia.